Morphic Holding Inc
NASDAQ:MORF

Watchlist Manager
Morphic Holding Inc Logo
Morphic Holding Inc
NASDAQ:MORF
Watchlist
Price: 56.99 USD Market Closed
Market Cap: 2.9B USD

Operating Margin
Morphic Holding Inc

0%
Current
-3 107%
Average
-4.7%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
0%
=
Operating Profit
-213m
/
Revenue
0

Operating Margin Across Competitors

No Stocks Found

Morphic Holding Inc
Glance View

Market Cap
2.9B USD
Industry
Biotechnology

Morphic Holding Inc. is a biotech firm paving new roads in the world of medicine by focusing on integrins, a class of proteins that are critical in various cellular processes but have long eluded effective therapeutic targeting. Born from the fertile intellectual fields of Harvard, Morphic was fueled by decades of research in integrin science, spearheaded by scientific luminaries like Professor Timothy A. Springer. The company's mission is to create oral integrin therapies—drugs that manipulate these proteins to treat conditions such as fibrosis, autoimmune diseases, and cancer. The unique approach involves leveraging structural biology and advanced chemistry to develop small molecule inhibitors, which are orally available, as opposed to the biologics traditionally used in targeting integrins. This innovation is an answer to the persistent demand for more patient-friendly treatments, which could potentially revolutionize the way certain chronic conditions are managed. Morphic makes its financial strides through strategic partnerships and collaborations with major pharmaceutical companies that see promise in their cutting-edge technology. These alliances support Morphic not only with direct funding but also through developmental milestones and subsequent royalties from the commercial success of any approved therapies. A key partnership with AbbVie, for example, underscores the potential seen in Morphic's pipeline, particularly in addressing immuno-inflammatory diseases. Furthermore, by continually advancing its proprietary MORF-057 and other candidates through clinical trials and regulatory pathways, Morphic aims to bring their innovative solutions to market. It's this blend of visionary science with pragmatic business acumen, underlined by robust intellectual property and productive alliances, that shapes Morphic's strategy in carving out a niche in the competitive biotech landscape.

MORF Intrinsic Value
Not Available
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
0%
=
Operating Profit
-213m
/
Revenue
0
What is the Operating Margin of Morphic Holding Inc?

Based on Morphic Holding Inc's most recent financial statements, the company has Operating Margin of 0%.

Back to Top